Navigation

    Forum

    • Register
    • Login
    • Search
    • Categories
    • Recent
    • Popular
    • Users
    • Groups

    564 - Based on advisory board recommendations for supportive tools, a company would like to create an unbranded "reference tool" which documents the metabolic pathways for drugs in a particular therapeutic area. This would be a service item distributed by the representatives. Information would be taken primarily from Product monographs and in a few cases, the literature. Is there any reason this would not be allowed? what would be the constraints?

    Claims & Support/References for Claims
    1
    1
    95
    Loading More Posts
    • Oldest to Newest
    • Newest to Oldest
    • Most Votes
    Reply
    • Reply as topic
    Log in to reply
    This topic has been deleted. Only users with topic management privileges can see it.
    • Jennifer Carroll
      Jennifer Carroll last edited by

      It is feasible to create a piece which includes a side-by-side comparison of product properties such as metabolic pathways. These comparisons are reviewed based on section 5.10.2 of the PAAB code which specifies that the information must be from the individual Product Monographs, we would question the use of other sources for this type of comparison. We caution that the presentation should not imply comparative clinical significance, and must be complete, in that other data relevant to the presentation also contained in the Product Monographs must not be omitted. This is also critical when creating an unbranded (i.e. editorial) tool as the piece must contain objective and balanced information with no emphasis on information about the sponsor’s product. We caution that selectively choosing a product property/feature (e.g. metabolic pathways), which may create a comparison that is beneficial to the sponsor’s product will not be acceptable in an unbranded context. A good rule of thumb is, if you can identify the sponsors product based on the information presented, then it is not an editorial (s. 7.5).

      1 Reply Last reply Reply Quote 0
      • First post
        Last post